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Summary 
AMP-activated protein kinase (AMPK) functions as a signaling hub to balance energy 
supply with demand. Phosphorylation of activation loop Thr172 has been considered as 
an essential step in AMPK activation. In this issue of Chemistry & Biology, Scott and 
colleagues show that the small molecule direct AMPK activator, A-769662, bypasses this 
phosphorylation event, and acts synergistically with AMP on naive AMPK. 
 
Main text 
Maintaining cellular energy balance is a key process for cell function and survival. Over 
the recent years, the AMP-activated protein kinase (AMPK) has emerged as a major 
regulator of cellular energy homeostasis. This serine/threonine kinase,evolutionary 
conserved in all eukaryotes, integrates multiple extra- and intracellular input signals 
directly or indirectly linked to limited energy availability to coordinate a wide array of 
compensatory, protective and energy-sparing responses at the cellular, organ and 
organism levels. AMPK isubiquitously expressed and exists as 
aheterotrimericcomplexcomprising a catalytic -subunit, a scaffolding -subunit and a 
regulatory -subunit. 
 
The AMPK activation mechanism was so far considered to involve two steps: an 
obligatory covalent phosphorylation of the α-subunit Thr172 in the so-called activation 
loop of the kinase domain, and a stimulatory allosteric binding of AMPto cystathionine-
beta-synthase (CBS) motifsin the γ-subunit. Covalent activation is complex, since it 
involves stimulated phosphorylation by several upstream kinases (LKB1, CaMKKβ) and 
inhibited dephosphorylation by phosphatases, both favored by β-subunit myristoylation 
and binding of AMP (and to a lesser extend ADP) to the different allosteric activation 
siteswithin the γ-subunit(Oakhill, et al., 2011; Xiao, et al., 2011).There seems to exist a 
delicate phosphorylation/dephosphorylation equilibrium, where the dephosphorylation 
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step is of major regulatory importance. However, not much is known about the nature of 
the phosphatases as itmay depend on both cell type and the environmental 
conditions.Allosteric activation of AMPK is even more intricate, since it is orchestrated 
by various structural elements in different AMPK subunits (Figure 1). Crystal structures 
of AMPK bound to either AMP or ATP revealed that only three of the four potential 
nucleotide-binding sitesin the -subunit contribute to nucleotide regulation(Chen, et al., 
2012; Xiao, et al., 2013; Xiao, et al., 2011). Since the activating ligand is bound on the γ-
subunit and the kinase domain is in the α-subunit, intersubunit communication has to 
occur when switching to fully active states (Figure 1). Valuable insight has been 
provided by core structures of AMPK heterotrimersshowing AMP induced 
conformational changes in the AMPK holocomplex and even the γ-subunit (Figure 1) 
(Chen, et al., 2012). Important regulatory features for this conformational 
switchareprovided by -subunit flexible components, the autoinhibitory domain (AID) 
and the -RIM/-hook interacting with the exchangeable nucleotide-binding sites on 
the -subunit, offering a signaling mechanism for nucleotide allosteric regulation(Chen, 
et al., 2012; Chen, et al., 2013; Xiao, et al., 2013; Xiao, et al., 2011).Given these complex 
regulatory mechanisms, it is not surprising that despite intense research the AMPK 
“activation switch” is still not entirely understood. 
 
Because of its critical role in maintaining cellular energy homeostasis, AMPK has 
attracted broad interest as a prime target for pharmacological intervention in several 
energy-related pathologies.Thishas led to increased efforts to develop direct AMPK-
activating drugs. In this issue of Chemistry and Biology, (Scott, et al., 2014) refine the 
mechanism of action of the first described small molecule direct AMPK activator, the 
thienopyridone drug A-769662,identified by Abbott laboratories (Cool, et al., 2006). 
Previous studies have reported that A-769662activates AMPK both allosterically and by 
inhibiting the dephosphorylation of AMPK on Thr172(Cool, et al., 2006; Sanders, et al., 
2007). However, in contrast to adenine nucleotides, A-769662 does not bind the γ-
subunit but requires the 1 regulatory subunit and its autophosphorylation at Ser108 
within the carbohydrate bindingmodule (CBM) (Figure 1)(Sanders, et al., 2007; Scott, et 
al., 2008). 
 
Previous studies reported one intriguing observation: A-769662 can trigger robust 
phosphorylation of the AMPK downstream target acetyl-CoA carboxylase in hepatocytes 
in absence of -subunit Thr172 phosphorylation (Foretz, et al., 2010; Goransson, et al., 
2007), raising some doubt about the requirement of AMPK activation loop 
phosphorylation for A-769662 action. (Scott, et al., 2014)nowusecatalytically 
inactive,bacterially expressed AMPK 111, which is not phosphorylated on Thr172, 
also showing a 65-fold activation with A-769662.However, other studies demonstrated 
that purified liver AMPK treated with phosphatase was refractory to A-769662 allosteric 
activation, suggesting that phosphorylation at another site is required for drug 
activation. Scott and colleagues now reveal that bacterially expressed AMPK 111 is 
strongly phosphorylated at -subunit Ser108, a phosphosite already linked to A-
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769662activation (Sanders, et al., 2007). Indeed, AMPKT172A/S108E and AMPKT172A/S108D 
mutants lacking phosphorylation at Thr172, but mimicking the one at S108, and treated 
in addition with  phosphatase, retained full activation by A-769662, demonstrating that 
phosphorylation on -subunit Ser108 alone is sufficient to render AMPK sensitive to A-
769662 allosteric activation(Figure 1, bottom).The authors also identify Ser108 
phosphorylation as a cis-autophosphorylationevent, without excluding the existence of a 
specific upstream kinase, but nevertheless raising questionsabout A-769662 effects in 
vivo. Indeed, if -subunit Ser108 is only autophosphorylated, it is entirely dependent on 
AMPK activity. This would explain why A-769662 activation is completely blunted in 
cells lacking LKB1 (Foretz, et al., 2010; Goransson, et al., 2007). 
 
Foretzet al.(Foretz, et al., 2010) had previously found that a combined treatment with 
the two AMPK activators A-769662 and the AMP analog 5-aminoimidazole-4-
carboxamide 1--D-ribofuranoside (AICAR), which act on different binding sites (-CMB 
and -CBS, respectively), exhibits a synergistic effect on AMPK phosphorylation and its 
downstream targets. Scott and colleagues next looked to extend their findings and tested 
whether combiningA-769662 and AMP has synergistic effects on activation of AMPK 
complexes containing AMPKT172A/S108E, AMPKT172A/S108D and AMPKT172A/S108A mutants. 
Here they employed recombinant AMPK complexes expressed in mammalian cells 
containing all post-translational modifications (e.g., myristoylation of -subunit) 
required to fully activateAMPK. Interestingly, A-769662-activation of AMPKT172A/S108E 
and AMPKT172A/S108D was further increased two to four-fold when combined with AMP. A 
surprising finding was the dramatic activation of AMPKT172A/S108Amutant following 
incubation with both A-769662 and AMP. This result is unexpected and novel. The 
authors demonstrate for the first time that AMPK can be activated in the absence 
ofphosphorylation at both -subunit Ser108 and -subunit Thr172.This synergistic 
AMPK activation was not mediated by autophosphorylation and occured exclusively via 
an allosteric mechanism. Another important finding is that the combined action of 
A769662 and AMP is entirely dependent on -CBM as AMPKT172A mutants lacking this 
regulatory domain are insensitive to synergistic allosteric activation. One plausible 
explanation is that A-769662 binding is critical to induce a conformational change in the 
AMPK holocomplexleading to the rearrangement and stabilization of the 
unphosphorylated activation loop to enhance AMPK activation upon AMP binding 
(Figure 1). This is consistent withthe recent structural studies showing that A-769662 
binding facilitates movement in the C-helix in the kinase domain to interact with the C-
interacting helix in the CBM, thus making an important contribution in the allosteric 
activation of AMPK (Xiao, et al., 2013). Strikingly, ADP, which does not cause AMPK 
Thr172 phosphorylation (Oakhill, et al., 2011; Xiao, et al., 2011), was unable to activate 
AMPKT172A/S108A mutant when combined with A-769662.To dig deeper in the mechanism 
of AMPK conformational changes, Scott and colleagues examined the role of individual 
CBS domains within the -subunit. When -subunit residues Asp90 (site 1), Asp245 (site 
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3) and Asp317 (site 4) were individually exchanged with Ala, synergistic activation 
induced by the combined action of A-769662 and AMP is severely blunted. 
 
Collectively, Scott and colleagues report how AMPK can be activated via a purely 
allosteric mechanism, bypassing the requirement of -subunit Thr172 and -subunit 
Ser108 phosphorylation.These findings are highly relevant for the development of 
specific directly-acting AMPK agonists andthe future direction of AMPK-based therapy 
in disease-focused research. This study is also critical to our understanding of how to 
target AMPK pharmacologically, depending on the cellular context (e.g., genetic loss of 
upstream kinase, expression of 1- and 2-subunits). There have been two recent 
reports evaluating the functional effects of A-769662 in combination with AICARor 
indirectAMPK activators (metformin, phenformin, oligomycin and hypoxia) acting via 
the elevation of cellular AMP levels.Consistent with enhanced AMPK activation by co-
treatment, inhibition of hepatic lipogenesis(Ducommun, et al., 2014)and activation of 
cardiac glucose transport(Timmermans, et al., 2014)were greatly improved compared 
with A-769662 alone. These results reinforce the view that combinatorial treatments 
would be of value to enhance AMPK activation. In addition, such treatments could help 
to reduce the amount of drugs administrated to patients and better balance tolerability 
and efficacy. Future research will have to elucidate the beneficial effects of metformin in 
combination with various AMPK activators targeting the A-769662 binding site for 
patients suffering of type 2 diabetes, insulin resistance, cardiovascular diseases and also 
cancer. 
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FIGURE LEGEND 
 
Figure 1: AMPK activation. Binding of the activating AMPK ligands AMP (γ-subunit) 
and A-769662 (β-subunit) has to be transduced to the α-subunit kinase domain for 
activation, involving conformational changes (see arrows). Top: AMPK subunits α 
(green), β (blue) and γ (magenta) (PDB 1CFF; (Xiao, et al., 2013)) with α-subunit kinase 
domain, activation loop (AL), and regulatory interacting motif (RIM, (Chen, et al., 2013)) 
indicated (dark green) and β-subunit carbohydrate binding module (CBM) labeled; 
sequences missing in the structure (dashed) include the α-auto-inhibitory domain (AID). 
The figure shows (in spacefill representation) the activation-relevant phosphosites (α-
T172 in the activation loop, and β-S108 in the CBM; red-brown) and ligands co-
crystallized in the structure: allosteric AMPK-activators A-769662 (red) and AMP 
(orange/yellow), and the kinase inhibitor Staurosporine in the active site (green). 
Bottom: Table summarizing the effect of phosphorylation or mutation of α-subunit 
T172 and β-subunit S108 on AMPK activation by AMP, A-769662, or both(Scott, et al., 
2014). 
γS108AS108E/D S108A
✔ ✗ ✗ ✗ ✗
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✔ ✔ ✔ ✔ ✔
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